25 Oct Stemina Biomarker Discovery, Inc, published in Frontiers in Psychiatry
Recent work from Stemina Biomarker Discovery, Inc, is published in Frontiers in Psychiatry regarding the Children’s Autism Metabolome Project (CAMP). The CAMP study carried out metabolomic analyses on plasma samples from a large cohort of children, ages 18 to 48 months. Samples from 499 autistic and 209 typically developing children were collected in a highly annotated, case-controlled study and analyzed using quantitative liquid chromatography/tandem mass spectrometry.
This new paper builds on previous work and provides new insights into subtypes of potential dysregulation in the metabolism of autistic children. Metabolomic analyses hold the promise for the discovery of biomarkers that may prove useful for diagnosis, clinical monitoring and ultimately understanding the causes of autism.
Elizabeth Donley of Stemina – “Our hope is that this research will contribute to a precision medicine approach with the goal of more targeted and effective treatments for the challenges faced by autistic individuals.”